LEQEMBI Market Sales Reflect Growing Confidence In Disease-Modifying Alzheimer’S Treatments| Delveinsight
LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...
5 Stocks With the Largest Fair Value Estimate Cuts After Q4 Earnings
Among the stocks on Morningstar’s list, the average change in fair value estimate was a 1.99% increase, above the 10-year ...
Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)
TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...
Drugmaker Eisai will cut 57 jobs at North Jersey headquarters
Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S. workforce. The New ...
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.
JCN Newswire9h
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...